Kawanishi Hideki, Kawaguchi Yoshindo, Fukui Hiroyoshi, Hara Shigeko, Imada Akio, Kubo Hitoshi, Kin Masao, Nakamoto Masahiko, Ohira Seiji, Shoji Takao
Tsuchiya General Hospital, Hiroshima, Japan.
Am J Kidney Dis. 2004 Oct;44(4):729-37.
Encapsulating peritoneal sclerosis (EPS) is recognized as a rare but serious complication of peritoneal dialysis (PD). The aim of this study was to determine the incidence, clinical features, and mortality rate of EPS.
The authors requested the registration of all PD patients in facilities across Japan where more than 10 patients were treated with PD in this prospective multicenter study. During the 4-year study, the incidence of EPS was observed in the enrolled patients.
A total of 1,958 patients who were treated with PD in 57 facilities were followed up from April 1999 through March 2003. EPS occurred in 48 patients, corresponding to an overall incidence of 2.5%. In 33 of the 48 (68.8%) patients, EPS was found after discontinuation of PD. The incidence (and mortality rate) of EPS was 0%, 0.7% (0%), 2.1% (8.3%), 5.9% (28.6%), 5.8% (61.5%), and 17.2% (100%) in patients who had undergone PD for 3, 5, 8, 10, 15, and more than 15 years, respectively. The recovery ratio with total parenteral nutrition, corticosteroids and surgical treatment were 0%, 38.5%, and 58.3%, respectively. Eighteen patients (37.5%) died, 22 (45.8%) recovered, and the status of the other 8 (16.7%) remained unchanged.
The results of this prospective multicenter study showed that the incidence of EPS was 2.5% within a 4-year observation period and that two thirds of the cases were diagnosed after discontinuation of PD. Because of the current progress in diagnostic technology and therapeutic methodology, it appears that PD can be continued successfully with an acceptable, low risk for EPS for at least 8 years, whereas stricter caution is required for patients receiving PD for longer periods.
包裹性腹膜硬化(EPS)是腹膜透析(PD)一种罕见但严重的并发症。本研究旨在确定EPS的发病率、临床特征及死亡率。
在这项前瞻性多中心研究中,作者要求日本各地接受超过10例患者进行PD治疗的机构登记所有PD患者。在4年的研究期间,观察入组患者中EPS的发病率。
1999年4月至2003年3月,对57个机构中接受PD治疗的1958例患者进行了随访。48例患者发生EPS,总发病率为2.5%。48例患者中的33例(68.8%)在PD停止后发现EPS。接受PD治疗3年、5年、8年、10年、15年及超过15年的患者中,EPS的发病率(及死亡率)分别为0%、0.7%(0%)、2.1%(8.3%)、5.9%(28.6%)、5.8%(61.5%)和17.2%(100%)。接受全胃肠外营养、皮质类固醇和手术治疗的恢复率分别为0%、38.5%和58.3%。18例患者(37.5%)死亡,22例(45.8%)康复,另外8例(16.7%)病情未变。
这项前瞻性多中心研究结果表明,在4年观察期内EPS发病率为2.5%,且三分之二的病例在PD停止后被诊断出。由于目前诊断技术和治疗方法的进展,似乎至少8年内可以成功继续进行PD,且EPS风险可接受且较低,而对于接受PD治疗时间更长的患者则需要更严格的谨慎。